New Treatment Offers Potentially Promising Results for the Possibility of Slowing, Stopping, or Even Reversing Parkinson’s Disease

February 27, 2019 - Amsterdam, NL – A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Parkinson's disease. The study investigated whether boosting the levels of a naturally-occurring growth factor, Glial Cell Line Derived Neurotrophic Factor (GDNF), can regenerate dying dopamine brain cells in patients with Parkinson's and reverse their condition, something no existing treatment can do. Potentially promising results of the third arm of the trials, an open access open-label extension study, are reported in the Journal of Parkinson's Disease. More...

February 27, 2019

Documenting and Decoding the Dynamics Between Work and Pain

A special issue of WORK: A Journal of Prevention, Assessment & Rehabilitation looks at factors around the experience and management of pain in workplaces around the world

February 25, 2019 - Amsterdam, NL – Workers suffering from chronic pain takes an immense toll on both employees and employers. Whether the pain that individuals experience is physical or psychological, constant or intermittent, or caused by work conditions or brought to the job, its effect on their productivity and wellbeing is a huge problem. Not surprisingly, work and pain are the subjects of a growing body of research, as technological advances transform healthcare at the same time as they created new challenges. More...

February 25, 2019

New Drug for Duchenne Muscular Dystrophy Clears Phase 1 Clinical Trial Testing in Boys

Medication targets NF-κB, a key link between loss of dystrophin and disease progression, and may benefit all DMD patients regardless of genetic mutation, according to research published in JND

February 21, 2019 - Amsterdam, NL – Patients with Duchenne muscular dystrophy (DMD) have few treatment options. Medications currently available or in development either target only a subset of DMD patients with a particular genetic mutation or cause significant side effects. The investigational drug edasalonexent, an oral NF-κB inhibitor, has the potential to slow the progression of the disease for all patients with DMD. The results of a Phase I clinical trial published in the Journal of Neuromuscular Diseases indicate that the drug was well tolerated with no safety issues in boys with DMD, paving the way for further clinical testing. More...

February 21, 2019

Can We Repair the Brain? The Promise of Stem Cell Technologies for Treating Parkinson’s Disease

Despite challenges, new advances in stem cell biology and genetic engineering show potential for better cell replacement therapies, say experts in a special supplement to JPD

February 14, 2019 - Amsterdam, NL – Cell replacement may play an increasing role in alleviating the motor symptoms of Parkinson's disease (PD) in future. Writing in an open access special supplement to the Journal of Parkinson's Disease, experts describe how newly developed stem cell technologies could be used to treat the disease and discuss the great promise, as well as the significant challenges, of stem cell treatment. More...

February 14, 2019